• Citer

Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer

par Lalami, Yassine ;Garcia, Camillo;Flamen, Patrick ;Ameye, Lieveke;Paesmans, Marianne ;Awada, Ahmad
Référence Head & neck, 38, 3, page (347-354)
Publication Publié, 2016-03

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer
Auteur:	Lalami, Yassine; Garcia, Camillo; Flamen, Patrick; Ameye, Lieveke; Paesmans, Marianne; Awada, Ahmad
Informations sur la publication:	Head & neck, 38, 3, page (347-354)
Statut de publication:	Publié, 2016-03
Sujet CREF:	Oto-rhino-laryngologie
Mots-clés:	antiangiogenic drugs
	fluorodeoxyglucose (FDG) positron emission tomography (PET)
	head and neck cancer
	sorafenib
Note générale:	SCOPUS: ar.j
	FLWIN
Langue:	Anglais
Identificateurs:	urn:issn:1043-3074
	info:doi/10.1002/hed.23898
	info:scp/84958109867
	info:pmid/25332069